baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Knock-Out ABBV/ DE000SU9ZD93 /

06/06/2024 21:46:17	Chg.-0.330	Bid21:59:34	Ask21:59:34	Underlying	Strike price	Expiration date	Option type
6.170EUR	-5.08%	- Bid Size: -	- Ask Size: -	AbbVie Inc	235.0147 USD	31/12/2078	Put

GlobeNewswire 05/06 CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law abou...

GlobeNewswire 05/06 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

GlobeNewswire 05/06 OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...

GlobeNewswire 04/06 Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 04/06 BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

GlobeNewswire 03/06 Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

GlobeNewswire 03/06 ACQUISITION NEWS: Cerevel’s (Nasdaq: CERE) $45 Merger Offer is Being Investigated for Being Too Low,...

GlobeNewswire 01/06 CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation ...

GlobeNewswire 30/05 OSE Immunotherapeutics Provides Business and Corporate Update

GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 28/05 Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Imp...

GlobeNewswire 28/05 CEREVEL THERAPEUTICS ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: C...

GlobeNewswire 28/05 Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

GlobeNewswire 25/05 CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law ...

GlobeNewswire 24/05 Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7...

GlobeNewswire 23/05 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...

GlobeNewswire 22/05 Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physic...

GlobeNewswire 22/05 Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...

GlobeNewswire 22/05 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire 22/05 Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...

GlobeNewswire 22/05 Anavex Life Sciences Announces Expansion of Leadership Team

GlobeNewswire 22/05 OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treat...

GlobeNewswire 21/05 COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

GlobeNewswire 21/05 BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by Ab...

GlobeNewswire 21/05 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Soc. Generale Knock-Out ABBV/ DE000SU9ZD93 /

If you wish to receive reply to your feedback, please provide your email address.